Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age

• Published in: Vaccine Vol. 26; no. 38; pp. 4940 - 4946
• Main Authors: Block, Stan L., Yogev, Ram, Hayden, Frederick G., Ambrose, Christopher S., Zeng, Wen, Walker, Robert E.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 08.09.2008; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adult; Age; Age Factors; Allergy and Immunology; Antibodies, Viral - blood; Applied microbiology; Biological and medical sciences; Child; Child, Preschool; Consent; Demography; Disease; Female; Fundamental and applied biological sciences. Psychology; Humans; Immunization; Immunogenicity; Influenza; Influenza A virus - immunology; Influenza A virus - isolation & purification; Influenza A virus - physiology; Influenza B virus - immunology; Influenza B virus - isolation & purification; Influenza B virus - physiology; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - prevention & control; Live attenuated influenza vaccine; Male; Metabolic disorders; Microbiology; Middle Aged; Miscellaneous; Review boards; Shedding; Stem cells; Time Factors; Vaccination; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Attenuated - administration & dosage; Vaccines, Attenuated - adverse effects; Vaccines, Attenuated - immunology; Virology; Virus Shedding; United States > US; Immunogenicity; Shedding; Live attenuated influenza vaccine; Orthomyxoviridae; Vaccine; Influenzavirus; Infection; Virus; Viral disease; Dissemination; Influenza; Attenuated strain; Age

Live attenuated influenza vaccine (LAIV) is indicated for influenza prevention in persons 2–49 years of age. This study describes the incidence and duration of vaccine virus shedding and serum immune responses after receipt of LAIV. A single open-label dose of trivalent LAIV was administered intrana...